Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

Description

The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.

Conditions

Pancreas Adenocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.

Safety and Efficacy of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma: Open Label Prospective Randomized Clinical Trial

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

Condition
Pancreas Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Pennington

Capital Health Medical Center-Hopewell, Pennington, New Jersey, United States, 08534

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Able to sign the informed consent and understand the consenting process
  • * Completed neoadjuvant chemotherapy regimen
  • * Patient is 18 years of age and older
  • * Eastern Cooperative Oncology Group (ECOG) Status of 0-1.
  • * Patient has a diagnosis of Stage I to Stage III pancreatic cancer cytologically or pathologically confirmed per American Joint Committee on Cancer (AJCC) staging criteria and NCCN guidelines, based on radiographic imaging or exploratory laparoscopic surgery, low degree of arterial involvement (CA, CHA, SMA) and no aorta involvement.
  • * Patients who are deemed eligible for IMRT or SBRT and approved to receive radiation therapy by multidisciplinary tumor board
  • * Patient shows no evidence of disease progression to distant metastasis based on NCCN.
  • * Negative pregnancy test
  • * Pregnant or lactating female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 6 months after the last dose of radiation therapy.
  • * Resectable pancreatic cancer (See addendum, NCCN Guidelines 2021, PANC-2)
  • * Unresectable pancreatic cancer (See addendum, NCCN Guidelines 2021, PANC-6)
  • * Patients who are unable to tolerate general anesthetic with full skeletal muscle blockade.
  • * Patients with implanted cardiac pacemakers, defibrillators, electronic devices or implanted devices with metal parts in the thoracic cavity.
  • * Life expectancy of \< 1 year

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Capital Health System, Inc,

Shirnett Williamson, MD, PRINCIPAL_INVESTIGATOR, Capital Health System, Inc

Study Record Dates

2027-06-22